New hope for kids with rare bone marrow failure: drug combo aims to restore blood cells
NCT ID NCT07001254
First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 16 times
Summary
This study tests whether adding romiplostim to standard immunosuppressive therapy helps children and young adults (ages 2–21) with severe aplastic anemia produce healthy blood cells. Participants have either newly diagnosed or hard-to-treat disease. The main goal is to see if blood counts improve without transfusions after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.